ALFA Finder| Revenue growth | Q4 +22% YoY; FY26 +8% (Standalone). |
|---|---|
| Margins | EBITDA profile moving from ~11% toward 20% target. |
| Order book | Secured ₹823cr multi-year mandate. |
| Demand visibility | High visibility through multi-year mandates and recurring revenues. |
Growth
Q4 FY26 Revenue grew 22% (₹472cr); Medical Devices grew 31%; API grew 17%. Full year FY26 revenue rose 8%.
Outlook
Targeting 20%+ EBITDA margins via CDMO expansion; manufacturing capacity plan for ~1000 KL; secured ₹823cr multi-year mandate.
Risks
API pricing remained volatile; FY26 PAT dropped 35% YoY to ₹66cr due to manufacturing scale-up and strategic investments.
Earnings Call filed with NSE, NSE: MOREPENLAB. Summary written with AI assistance from the document.
Morepen Laboratories Ltd: key numbers
- Share price
- ₹96.74
- Market cap
- ₹5,301 Cr
- Revenue (annual)
- ₹1,806 Cr
- Net profit (annual)
- ₹94.88 Cr
- P/E (TTM)
- 28.1×Sector 43.8×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 3.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Morepen Laboratories Ltd
All →Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
Morepen Laboratories Management Change
Morepen Laboratories announced promotions effective 27 October 2026 for two senior management personnel. Charanjeet Chitakara moves to Assistant Vice President (Quality Control) and Vivan Prashar to Vice President (Projects & Engineering).
Morepen Laboratories Other Announcement
Morepen filed its Q2FY27 Monitoring Agency Report confirming Nil deviation in QIP proceeds utilization. The company spent ₹1.12 crore on modernization and expansion during the quarter.
Morepen Laboratories Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs755 Cr (+81%), PAT Rs89 Cr (+117%), EBITDA margin 17.45% (+897bps). H1 revenue Rs1,330 Cr (+57%). CDMO scale-up drives mix.
Morepen Laboratories Results Update
Morepen hit record Q2 FY27 revenue up 81% and EBITDA up 273%, driven by CDMO scale-up. H1 EBITDA reached ₹220 Cr; API+CDMO capacity now 614 KL.
- API + CDMO manufacturing capacity
- 614 KL
Morepen Laboratories Q2 FY27 Results: Net Profit ₹88.9 Cr, Up 117.4% YoY
Morepen Laboratories Ltd reported revenue from operations of ₹746.5 Cr (+81.4% YoY) and net profit of ₹88.9 Cr (+117.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹88.9 Cr · +117.4% YoY